Curaleaf Holdings Inc (OTCMKTS: CURLF) has announced that its wholly-owned subsidiary, Adven GmbH, has entered into a planned Collaboration with Zambon GmbH, the German subsidiary of Zambon Spa.
The objective of Collaboration is to make medicinal cannabis cures obtainable to patients
The goal of the arrangement is to make medicinal cannabis cures obtainable to patients, with an early emphasis on neural treatments. The first usage will take off in Germany in Summer 2021.
“Our know-how in neurology and Curaleaf International’s understanding of the pharmaceutical dynamic procedures of cannabinoids deliver faultless settings to bring ground-breaking usage to patients,” said Marco Castino, Head of Region Europe in Zambon.
Since 2017, cannabis has been accepted for healing use in Germany and maybe recommended by medics for grave diseases. As a result, Germany is Europe’s leading market for medical cannabis. It is projected to be worth USD 2.1 billion by 2025.
“We are incessantly eyeing for habits to advance the life of repeatedly neurologically ill patients with our produces. Proposing modern treatment methods, such as co-medication, particularly in view of the development of these scientific pictures, is part of our vision to advance patients’ exists,” said Dirk Greshake, Zambon GmbH General Manager.
The company opens the second dispensary in New Jersey
Curaleaf announced the inaugural of Curaleaf Edgewater Park, the company’s second dispensary in New Jersey and 107th dispensary countrywide.
In addition, the company announced that its additional New Jersey farming facility, located in Winslow, finished its first yield and is now wholly functioning. The new site has trebled Curaleaf’s farming abilities to aid the current New Jersey medical market and the approaching adult-use market.
“We are excited to breed alongside New Jersey’s prosperous medicinal community and enlarge admission to best-in-class cannabis yields to patients in Edgewater Park,” said Joe Bayern, CEO of Curaleaf.
Curaleaf Edgewater Park is a 7,640 square foot dispensary suitably located off the Burlington Pike at 4237 Route 130 South and is open to all patients with a legal, medical card. Curaleaf has been serving New Jersey’s medical public since the inaugural of its Bellmawr dispensary in 2015, and the company forestalls opening a third dispensary in Central New Jersey later this summer. As a result, patients will have extended admission to Curaleaf’s varied line of award-winning product contributions counting proprietary floret, vapes, and ingestible yields.
 Spreads Availability of Medical Cannabis Products in Germany with Collaboration with Zambon GmbH){kind=link}